InMed (INM) director files Form 3, reports no ownership
InMed Pharmaceuticals (INM) disclosed an initial beneficial ownership filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InMed Pharmaceuticals (INM) disclosed an initial beneficial ownership filing. A director submitted a Form 3 indicating their status as a Director and reporting no securities beneficially owned as of the event date 10/09/2024.
The Form 3 was filed by one reporting person and lists no direct or indirect holdings in either non-derivative or derivative securities. The filing is signed "/s/ Neil Klompas" and dated 10/17/2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did InMed Pharmaceuticals (INM) file?
What is reported about the director’s holdings in INM?
What is the event date for this Form 3?
How many reporting persons are included?
Were any derivative securities disclosed?
Who signed the filing and when?
AI-generated analysis. How Rhea-AI works. Not financial advice.